The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non‐systemic vasculitic neuropathy: executive summary
Abstract
Non‐systemic vasculitic neuropathy (NSVN) is routinely considered in the differential diagnosis of progressive axonal neuropathies, especially those with asymmetric or multifocal features. Diagnostic criteria for vasculitic neuropathy, classification criteria for NSVN, and therapeutic approaches to NSVN are not standardized. The aim of this guideline was to derive recommendations on the classification, diagnosis, investigation, and treatment of NSVN based on the available evidence and, where evidence was not available, expert consensus. Experts on vasculitis, vasculitic neuropathy, and methodology systematically reviewed the literature for articles addressing diagnostic issues concerning vasculitic neuropathy and NSVN as well as treatment of NSVN and the small‐to‐medium vessel primary systemic vasculitides using MEDLINE, EMBASE, and the Cochrane Library. The selected articles were analyzed and classified. The group initially reached consensus on a classification of vasculitides associated with neuropathy. Non‐diabetic radiculoplexus neuropathy was incorporated within NSVN. The consensus definition of pathologically definite vasculitic neuropathy required that vessel wall inflammation be accompanied by vascular damage. Diagnostic criteria for pathologically probable vasculitic neuropathy included five predictors of definite vasculitic neuropathy: vascular deposits of IgM, C3, or fibrinogen by direct immunofluorescence; hemosiderin deposits; asymmetric nerve fiber loss; prominent active axonal degeneration; and myofiber necrosis, regeneration, or infarcts in peroneus brevis muscle biopsy (Good Practice Points from class II/III evidence). A case definition of clinically probable vasculitic neuropathy in patients lacking biopsy proof incorporated clinical features typical of vasculitic neuropathy: sensory or sensory‐motor involvement, asymmetric/multifocal pattern, lower‐limb predominance, distal‐predominance, pain, acute relapsing course, and non‐demyelinating electrodiagnostic features (Good Practice Points from class II/III evidence). Proposed exclusionary criteria for NSVN – favoring the alternate diagnosis of systemic vasculitic neuropathy – were clinicopathologic evidence of other‐organ involvement; anti‐neutrophil cytoplasmic antibody (ANCAs); cryoglobulins; sedimentation rate ≥100 mm/h; and medical condition/drug predisposing to systemic vasculitis (Good Practice Points supported by class III evidence). Three class III studies on treatment of NSVN were identified, which were insufficient to permit a level C recommendation. Therefore, the group reviewed the literature on treatment of primary small‐to‐medium vessel systemic vasculitides prior to deriving Good Practice Points on treatment of NSVN. Principal treatment recommendations were: (1) corticosteroid (CS) monotherapy for at least 6 months is considered first‐line; (2) combination therapy should be used for rapidly progressive NSVN and patients who progress on CS monotherapy; (3) immunosuppressive options include cyclophosphamide, azathioprine, and methotrexate; (4) cyclophosphamide is indicated for severe neuropathies, generally administered in IV pulses to reduce cumulative dose and side effects; (5) in patients achieving clinical remission with combination therapy, maintenance therapy should be continued for 18–24 months with azathioprine or methotrexate; and (6) clinical trials to address all aspects of treatment are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
Self-citationMicrovasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy
Dyck, P. J. B., Norell, J. E., & Dyck, P. J. (1999) · Neurology · doi:10.1212/wnl.53.9.2113 · Cited by 337
Self-citationSuperficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy
Collins, M. P., Mendell, J. R., Periquet, M. I., Sahenk, Z., Amato, A. A., Gronseth, G. S., Barohn, R. J., Jackson, C. E., & Kissel, J. T. (2000) · Neurology · doi:10.1212/wnl.55.5.636 · Cited by 200
Self-citationDyck, P. J. B. (2001) · Brain · doi:10.1093/brain/124.6.1197 · Cited by 169
Self-citationNonsystemic vasculitic neuropathy: Insights from a clinical cohort
Collins, M. P., Periquet, M. I., Mendell, J. R., Sahenk, Z., Nagaraja, H. N., & Kissel, J. T. (2003) · Neurology · doi:10.1212/01.wnl.0000082715.48844.3e · Cited by 163
Self-citationInflammatory vasculopathy in multifocal diabetic neuropathy
Saïd, G. (2003) · Brain · doi:10.1093/brain/awg029 · Cited by 133
Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome
Mathew, L., Talbot, K., Love, S., Puvanarajah, S. D., & Donaghy, M. (2006) · QJM · doi:10.1093/qjmed/hcl125 · Cited by 72
Progressive idiopathic axonal neuropathy
Notermans, N. C., Jansen, G. H., Wokke, J. H. J., Saïd, G., & Vrancken, A. F. J. E. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0275-9 · Cited by 40
Self-citationImmunosuppressive treatment for non-systemic vasculitic neuropathy
Vrancken, A. F. J. E., Hughes, R. A., Saïd, G., Wokke, J. H. J., & Notermans, N. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006050.pub2 · Cited by 25
Self-citation
Cited by
Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations
Koike, H., Tanaka, F., & Sobue, G. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834a87b7 · Cited by 105
Self-citation
Metadata
- Authors
- Collins, M. P., Dyck, P. J. B., Gronseth, G. S., Guillevin, L., Hadden, R. D. M., Heuss, D., Léger, J., Notermans, N. C., Pollard, J. D., Said, G., Sobue, G., Vrancken, A. F. J. E., & Kissel, J. T.
- Venue
- Journal of the Peripheral Nervous System
- Publisher
- Wiley
- Published
- 2010-09
- Volume
- 15
- Issue
- 3
- Pages
- 176-184
- ISSN
- 1085-9489 (ISSN-L)
- 1529-8027
- OpenAlex
- W2000509743
- Cited by
- 288
- References
- 9
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non‐systemic vasculitic neuropathy: executive summary. https://app.cochat.ai/papers/10.1111/j.1529-8027.2010.00281.x
- The paper
- Collins, M. P., Dyck, P. J. B., Gronseth, G. S., Guillevin, L., Hadden, R. D. M., Heuss, D., Léger, J., Notermans, N. C., Pollard, J. D., Said, G., Sobue, G., Vrancken, A. F. J. E., & Kissel, J. T. (2010). Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non‐systemic vasculitic neuropathy: executive summary. Journal of the Peripheral Nervous System. https://doi.org/10.1111/j.1529-8027.2010.00281.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.